Serum Prostatic Specific Antigen Levels among Adult Male Patients Seen at Two Nigerian Tertiary Hospitals
Asian Journal of Research and Reports in Urology,
Background: The clinical utilization of PSA test in early detection and monitoring therapy of cancer of prostate is influenced by demographic factors like age, geographical location, metabolic factors, method of analysis and sensitivity and specificity of the test. Hence, we retrospectively compared the serum PSA levels of adult male patients seen at two Nigerian tertiary hospitals.
Methodology: The retrospective study was conducted at two Nigerian tertiary hospitals, Federal medical centre, Yola and Makurdi between January and December 2019. Study participants were adult males with lower urinary tract symptoms presented at the Urology units and referred to the hospital chemical pathology laboratories for total PSA assay using quantitative method, Time –resolved Flourence immunoassay, Bioscience Diagnostic Technology Ltd, China. Data extracted includes,age, clinical details, and PSA levels. Descriptive analysis using SPSS version 21.0 was employed. A total of 430 data were extracted, 201 from Yola and 229 from Makurdi
Result: Significant difference was observed in the mean age, 61.67+0.09years vs 58.61+58.61years(p=0.009) and mean serum PSA level of patients21.88+3.04ng/ml vs 14.81+0.74ng/ml(p=0.041). Significant difference was observed in the mean serum PSA level(1.33+0.09ng/ml vs 1.65+0.08ng/ml)(p=0.011) of patients with PSA level (LUTS) within the range of <4ng/ml,and those with >10ng/ml(65.88+0.09 vs 40.43+3.66ng/ml)(p=0.003). 211(49.1%, 51.7 vs 46.7%)had PSA level 4ng/ml, 86(20%, 17.9% vs 21.8%)within 4-10ng/ml and 133(30.9%, 30.3 vs 31.4%) had >10ng/ml. No significant correlation was observed between PSA level and age, but increased with advancement in age. Diabetes Mellitus(DM)(0.9%) and co-existence of DM and hypertension(2.0%) were recorded as comorbidities
Conclusion: The study findings affirmed high PSA level and increase with age in suscepted cases of cancer of prostate. it serves as a baseline epidemiological template for further comprehensive study for better understanding of PSA level in clinical diagnosis and create awareness of the disease.
- Serum prostatic specific antigen
- cancer of prostate
- adult males with Lower Urinary Tract Symptoms(LUTS)
- Yola and Makurdi
How to Cite
Wu I, Modlin CS. Disparities in prostate cancer in African American men: what primary care physicians can do. Cleve Clin J Med. 2012;79(5):313–20.
Ogunbiyi OJ . Impact of health system challenges on prostate cancer control: Health care experiences in Nigeria Infect Agent Cancer. 2011;6(Suppl 2):S5
Lilja H. Biology of prostate-specific antigen. Urology.2003;62(5 Suppl 1): 27–33.
Klein LT, Lowe PC;The effect of prostatic manipulation on prostate –specific antigen levels.Urolo Clin North Am ,1997;24:293-7
Fowler JE Jr, Bigler SA, Kilambi NK, Land SA. Relationship between prostatic specific antigen and prostatic volume in black and white men with benign prostate biopies. Urology,1999; 53:1175-8
Malati T, Kumari GR. Racial and ethnic variation of PSA in global population: age specific reference intervals for serum prostate specific antigen in healthy South Indian males. Indian J Clin Biochem.,2004;19(1): 132–7.
Myothe J and Ivor I.Measurement of prostatic specific antigen(PSA) in serum by a two site immunometric method (Hydritech Tandem-R/Tandem-E PSA).In Catalona WJ, Clinical aspect of prostate cancer.New York Elservier, 1989:161-71
Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level
Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156- 1161
Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al.Serum prostate- specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;270(7): 860–4.
Ikuerowo SO, Ajala MO, Abolarinwa AA, Omisanjo OA.Age-specific serum prostate specific antigen ranges among apparently healthy Nigerian men without clinical evidence of prostate cancer. Niger J Surg. 2016;22(1): 5–8.
Amadi C, Ehimen P. Odum Age-specific serum prostate-specific antigen references range among healthy men in Port Harcourt, Nigeria: a retrospective hospital-based study Int J Res Med Sci. 2018; 6(2):417-421
Casey RG, Hegarty PK, ConroyIR, Rea D, Butler MR, Grainger R, TedMcDermott, and Thornhill JA The Distribution of PSA Age-Specific Profiles in Healthy Irish Men between 20 and 70 International Scholarly Research Network ISRN Oncology 2012; 2012,
Article ID 832109, 4 pages
Rabah DM, Farhat KH ,Al-Atawi MH B, Arafa MA. Age-Specific Reference Ranges of Prostate-Specific Antigen among Saudi Men as a Representation of the Arab Population Med Princ Pract 2019;28:242–246
Afogu EN, Sunday-Adeoye I, Ekwedigwe KC, Isikhuemen ME, Okenwa SC, Popoola SA, Eliboh MO, Amamilo IC Prostate Specific Antigen Screening among Men in Abakaliki, South East Nigeria Open Journal of Urology, 2017;7:79-85
Okolo CA, Akinosun OM, O.B. Shittu OB, Olapade-Olaopa EO, Okeke LI, AkangEEU and Ogunbiyi JO Correlation of Serum PSA and Gleason Score in Nigerian Men with Prostate Cancer African Journal of Urology, 2008;14(1):15 15-22
Ofoha CG and Magnus FE. Presentation, Characteristic and Co-morbidities of Men with Prostate Cancer in Nigeria. Journal of Advances in Medicine and Medical Research, 2018;31(5);1-7,2019
Adegun PT, Adebayo PB, Atiba SA (2015) The likelihood of having serum level of PSA of ‡4.0 ng/mL and ‡10.0 ng/mL in non-obese and obese Nigerian men with LUTS Asian Journal of Urology. 2015;2:158e162
Benson MC, Whang IS, Olsson CA, et al. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992;147:817- 821.
Catalona WJ, Richie JP, Ahman FR .Comparsion of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6630men. J Urol 1994;151:1283-90
Yunusa B, Abdullahi M, Mashi SA, Aji SA,Alhassan SU. Determination of the sensitivity and specificity of serum prostate-specific antigen in the diagnosis of prostrate cancer in Kano,Northwestern Nigeria. Niger J Basic Clin Sci. 2017;14:88-91.
Nadler RB. The case for prostate-specific antigen screening starting at age 40. Cancer. 2008;113(6):1278–81.
Abstract View: 54 times
PDF Download: 22 times